The Medical Marijuana Oversight Committee’s first 2026 interim meeting did not decide whether cannabis still belongs in Schedule I under South Dakota law. It did something more limited, and more useful: it put federal classification, program scale, and the absence of a state legal answer onto the official packet.¹
That is not a committee endorsement of any petition. It is the public record catching up to a statutory problem now sitting, stamped, at the Department of Health.
What was actually in the packet
The Legislative Research Council’s hearing-document page for the 2026 committee lists four attachments from the August 17 meeting in Pierre: a Department of Health program overview, an NCSL briefing on federal cannabis and hemp implications for the states, a public handout from Jim Sheehan, and the guest register.² Minutes, an agenda PDF, and an October meeting notice were not posted as of September 2, 2026.³
The thin packet matters. In November 2025 the same committee adopted a slate of policy motions that had not been posted in advance.⁴ August 17 was not that meeting. It was a status-and-federal-briefing meeting. The legal work was deferred.
What NCSL put on the table
Nicole Ezeh, law and public safety legislative director for the National Conference of State Legislatures, briefed the committee on the federal change. As SDPB reported the next morning, she described the action as limited: it moves certain products from Schedule I to Schedule III — FDA-approved drugs containing delta-9 THC from Cannabis sativa, and cannabis products subject to a state medical cannabis scheme.⁵
That description tracks the Justice Department’s April 23, 2026 order and the April 28 Federal Register final rule placing FDA-approved marijuana products, and marijuana subject to a qualifying state medical-marijuana license, in Schedule III.⁶ The same federal package left unlicensed bulk marijuana in Schedule I and set a separate administrative hearing on broader rescheduling.⁷ Adult-use cannabis was not converted into a federal medical program by that order.
The committee did not have to resolve the federal scheme. It only had to notice that South Dakota already runs a licensed medical program while Title 34-20B still applies the Schedule I test to the same plant.
What DOH put on the table
Whitney Brunner, administrator of the Office of Medical Cannabis, delivered the department’s program overview. Same-day reporting put current cardholders above 19,000.⁸ SDPB reported program revenue of about $2.6 million, most of it from cardholder fees.⁹ Later coverage of the same briefing recorded licensed home cultivators rising from 61 in fiscal year 2022 to 715 in fiscal year 2026, with caregiver cultivators moving from 22 to 37.¹⁰
Those figures are not a scheduling holding. They are the Department of Health telling the oversight committee that the medical program is no longer a pilot. The same department administers that program and is charged with applying the Schedule I criteria in SDCL 34-20B-11.¹¹
What the statute still says
South Dakota’s Schedule I test is not a press line. It is a three-part statutory command. To remain in Schedule I, a substance shall have a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for use under medical supervision.¹²
A state that licenses thousands of patients, scores of establishments, and hundreds of home cultivators is not a state that can treat “no accepted medical use” as an untouched fact. Federal placement of state-licensed medical cannabis in Schedule III does not automatically rewrite SDCL 34-20B-12. It does make the continued use of the 34-20B-11 test a question the Department can no longer pretend is theoretical.
SDCL 34-20B-27 already authorizes recommendations for addition, deletion, or rescheduling of scheduled substances.¹³ SDCL 1-26-15 requires each agency to provide for the filing and prompt disposition of a petition for a declaratory ruling on the applicability of any statutory provision.¹⁴ Department rules require the Department of Health to issue that ruling within sixty days of the petition or of any requested follow-up information.¹⁵
What Garcia said about October
Chairwoman Josephine Garcia told Dakota News Now that the next meeting would be in October and that the committee hoped to have the Attorney General testify on the future of medical marijuana. She also said federal guidance on tax policy and interstate commerce had not been established, which made it hard for lawmakers to draft around the change.¹⁶
That sentence is a description of legislative caution. It is not a substitute for a Department ruling on a state statute. Missing IRS or DEA commerce memos do not suspend SDCL 34-20B-11. They do not suspend ARSD 44:62:01:02. They do not answer whether cannabis still meets the three Schedule I criteria under South Dakota law.
What remains unanswered
On August 31, 2026, a petition asking the Department of Health to apply SDCL 34-20B-11 to cannabis, and to say whether Schedule I remains lawful, was delivered in person and stamped received by the Department at 3:33 p.m.¹⁷ The August 17 packet did not cite that filing, and this article does not claim the committee adopted it.
The filing and the meeting now sit in the same building. The meeting established official uncertainty. The petition asks for a written answer before the 2027 session starts drafting in the dark. Under the Department’s own rule, a ruling is due within sixty days of receipt or of any follow-up information the Department requests.¹⁸
If the Attorney General appears in October, the useful question is narrow. It is not a request for a federal tax forecast. It is whether cannabis still satisfies SDCL 34-20B-11 after federal recognition of accepted medical use for products under a state medical license, and after the Department’s own medical-cannabis program has licensed more than 19,000 patients. One question. The statute already supplies the test.
As of September 2, 2026, the Legislative Research Council has not posted August 17 minutes or an October date.¹⁹ Until those documents appear, the public record is the four-item packet, the contemporaneous press, the Schedule I statute, and a petition stamped August 31. That is enough to say the oversight committee put the classification problem on the table. Whether the State will answer or stall remains to be seen.
Footnotes
¹ S.D. Legislature, 2026 Medical Marijuana Oversight Committee, Hearing Documents (listing Aug. 17, 2026 attachments), https://sdlegislature.gov/Interim/Committee/501/HearingDocuments; Grant Green, SD Lawmakers Discuss How Medical Cannabis Program Can Improve, Dakota News Now (Aug. 17, 2026), https://www.dakotanewsnow.com/2026/08/17/sd-lawmakers-discuss-how-medical-cannabis-program-can-improve/.
² S.D. Legislature, supra note 1 (Jim Sheehan handout, Aug. 14, 2026; NCSL Federal Cannabis and Hemp State Implications, Aug. 14, 2026; DOH South Dakota Medical Cannabis Program Overview, Aug. 17, 2026; Aug. 17, 2026 Guest Register).
³ S.D. Legislature, 2026 Medical Marijuana Oversight Committee, https://sdlegislature.gov/Interim/Committee/501/Detail (no minutes or October notice posted as of Sept. 2, 2026).
⁴ Medical Marijuana Oversight Committee, 2025 Final Report; see also Jackson Dircks, Medical Marijuana Oversight Committee Critics Speak Out at Latest Meeting, SDPB (Nov. 5, 2025), https://www.sdpb.org/healthcare/2025-11-05/medical-marijuana-oversight-committee-critics-speak-out-at-latest-meeting.
⁵ C.J. Keene, How Federal Cannabis Scheduling Shakeup Impacts South Dakota Medical Marijuana Policy, SDPB (Aug. 18, 2026), https://www.sdpb.org/politics/2026-08-18/how-federal-cannabis-scheduling-shakeup-impacts-south-dakota-medical-marijuana-policy.
⁶ U.S. Dep’t of Justice, Justice Department Places FDA-Approved Marijuana Products and Products Containing Marijuana Subject to a Qualifying State-Issued License in Schedule III (Apr. 23, 2026), https://www.justice.gov/opa/pr/justice-department-places-fda-approved-marijuana-products-and-products-containing-marijuana; Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III, 91 Fed. Reg. 22,714 (Apr. 28, 2026).
⁷ Id.; Notice of Hearing on Proposed Rulemaking, Schedules of Controlled Substances: Rescheduling of Marijuana, 91 Fed. Reg. (Apr. 28, 2026) (hearing beginning June 29, 2026).
⁸ Green, supra note 1.
⁹ Keene, supra note 5.
¹⁰ Zach Nelson, Department of Health Concerned With Rapid Increase in Home Medical Marijuana Cultivator Licenses, KCCR (Aug. 31, 2026), https://www.kccrradio.com/2026/08/31/department-of-health-concerned-with-rapid-increase-in-home-medical-marijuana-cultivator-licenses/.
¹¹ SDCL 34-20B-11; SDCL ch. 34-20G.
¹² SDCL 34-20B-11.
¹³ SDCL 34-20B-27.
¹⁴ SDCL 1-26-15.
¹⁵ ARSD 44:62:01:01 to 44:62:01:02.
¹⁶ Green, supra note 1.
¹⁷ Jason Karimi, WeedPress Asks South Dakota Health Department to Rule Whether Schedule I Cannabis Still Fits the State’s Own Statute, WeedPress (Aug. 31, 2026), https://weedpress.org/2026/08/31/weedpress-asks-south-dakota-health-department-to-rule-whether-schedule-i-cannabis-still-fits-the-states-own-statute/ (petition delivered in person and stamped received by the Department of Health at 3:33 p.m., Aug. 31, 2026).
¹⁸ ARSD 44:62:01:02.
¹⁹ S.D. Legislature, supra note 3.
WeedPress: The Paper Trail 
Leave a comment